Total Payments
$38,967
2022 Payments
$2,620
Companies
2
Transactions
90
Payment Breakdown by Category
Consulting$27,750 (71.2%)
Other$10,875 (27.9%)
Travel$302.21 (0.8%)
Food & Beverage$40.50 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $27,750 | 68 | 71.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $10,875 | 11 | 27.9% |
| Travel and Lodging | $302.21 | 10 | 0.8% |
| Food and Beverage | $40.50 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $38,927 | 89 | $0 (2022) |
| Astellas Pharma US Inc | $40.50 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $2,620 | 5 | Novartis Pharmaceuticals Corporation ($2,620) |
| 2021 | $9,080 | 18 | Novartis Pharmaceuticals Corporation ($9,080) |
| 2019 | $1,047 | 4 | Novartis Pharmaceuticals Corporation ($1,007) |
| 2018 | $15,043 | 42 | Novartis Pharmaceuticals Corporation ($15,043) |
| 2017 | $11,177 | 21 | Novartis Pharmaceuticals Corporation ($11,177) |
All Payment Transactions
90 individual payment records from CMS Open Payments — Page 3 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/25/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $48.76 | General |
| Category: NEUROSCIENCE | ||||||
| 06/13/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 06/13/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $34.63 | General |
| Category: NEUROSCIENCE | ||||||
| 06/08/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 05/24/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 05/24/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $36.47 | General |
| Category: NEUROSCIENCE | ||||||
| 05/11/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 05/11/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $11.39 | General |
| Category: NEUROSCIENCE | ||||||
| 05/04/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 05/04/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $29.68 | General |
| Category: NEUROSCIENCE | ||||||
| 03/22/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 03/22/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $25.07 | General |
| Category: NEUROSCIENCE | ||||||
| 03/19/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 03/19/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $42.51 | General |
| Category: NEUROSCIENCE | ||||||
| 03/12/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 02/15/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 01/04/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: NEUROSCIENCE | ||||||
| 01/04/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $128.62 | General |
| Category: NEUROSCIENCE | ||||||
| 01/04/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $107.80 | General |
| Category: NEUROSCIENCE | ||||||
| 03/30/2017 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 03/30/2017 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Travel and Lodging | In-kind items and services | $59.92 | General |
| Category: NEUROSCIENCE | ||||||
| 03/30/2017 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Travel and Lodging | In-kind items and services | $4.00 | General |
| Category: NEUROSCIENCE | ||||||
| 03/23/2017 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 03/22/2017 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 03/10/2017 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: NEUROSCIENCE | ||||||
About Dr. Stuart Katz, M.D
Dr. Stuart Katz, M.D is a Urology healthcare provider based in Falls Church, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1912050840.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stuart Katz, M.D has received a total of $38,967 in payments from pharmaceutical and medical device companies, with $2,620 received in 2022. These payments were reported across 90 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($27,750).
Ad
Practice Information
- Specialty Urology
- Location Falls Church, VA
- Active Since 01/22/2007
- Last Updated 11/29/2011
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1912050840
Products in Payments
- GILENYA (Drug) $33,363
- MAYZENT (Drug) $5,564
- XTANDI (Drug) $40.50
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.